Brvyxxa

Portola Pharmaceuticals Inc (NASDAQ: PTLA) announced last Friday the FDA has approved Brvyxxa, its anti-coagulant candidate. Bevyxxa is an oral, once-daily Factor Xa inhibitor, was granted a Fast Track designation and approved under Priority review, which reduces the timeframe for review to...